The first injectable drug for the treatment of COVID-19 "Areplivir" was registered in Russia.
MOSCOW, November 12 - RIA Novosti. A drug for the coronavirus "Areplivir" has been registered in Russia , follows from the state register of medicines.
"Date of registration: 11/12/2021. It is allowed to enter into civil circulation up to five years," - follows from the drug card.
The drug for coronavirus infection "Areplivir" (international non-proprietary name "Favipiravir") was developed and produced at the Saransk plant "Biochemist" (part of the " Promomed " group ) in 2020.
In February 2021, the Ministry of Industry and Trade reported that since September the plant has increased the production of the drug tenfold, to one million packs per month, and plans to increase production to two million.
"Areplivir" is included in the methodological recommendations of the Ministry of Health for the treatment of coronavirus infection and is included in the list of vital and essential medicines. In addition, its outpatient use is permitted. The recommended price is 5060 rubles.